NeoGenomics (NEO) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and market positioning

• Focused exclusively on oncology diagnostics, with a strong presence in community settings where 80% of cancer patients are treated.

• Leadership in hematology leveraged to expand into solid tumor therapy selection and MRD markets, holding over 25% hematology market share.

• Three strategic pillars: expand from HEME into new markets, evolve offerings for community oncologists, and make targeted investments for growth and margin expansion.

• Breadth of test menu and community oncology focus differentiates from larger labs and specialty diagnostics.

• Mission centers on improving patient care and becoming the leading provider of comprehensive cancer testing and solutions.

Product innovation and launches

• Comprehensive test menu spans diagnosis to MRD, with new launches like PanTracer tissue and PanTracer liquid biopsy.

• RaDaR-ST MRD test launching in Q1, targeting a $20B+ market, with two indications approved and two more submitted for reimbursement.

• Five new products launched in 2023 are projected to contribute ~24% of 2025 clinical revenue.

• PanTracer tissue volumes doubled year-over-year, and liquid biopsy introduced in response to customer demand.

• Favorable reimbursement decisions and multiple patents support new product launches.

Community oncology and customer engagement

• Over 4,000 ordering accounts and 15% year-over-year growth in physicians ordering five or more tests.

• High Net Promoter Score (78) reflects strong physician satisfaction, driven by ease of ordering, report simplicity, and comprehensive test menu.

• Sales team expansion accelerates penetration among community oncologists, with increased ordering and headcount from 2023 to 2025.

• Targeted investments aim to drive top-line growth and margin expansion in the community setting.

• Community oncology is critical for health equity, cost-effectiveness, and personalized care.